400 Participants Needed

Exposure Therapy for OCD

Recruiting at 1 trial location
JM
Overseen ByJennie M Kuckertz, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Mclean Hospital
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to enhance the effectiveness of exposure therapy for individuals with Obsessive Compulsive Disorder (OCD). Researchers seek to identify specific techniques during therapy sessions that lead to the best outcomes. Participants will undergo exposure therapy, which involves confronting anxiety triggers in a controlled manner, and will provide feedback on their experiences. The trial is suitable for adults with OCD seeking exposure therapy at McLean Hospital or San Diego State University. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could improve therapy techniques for OCD.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that exposure therapy is safe for OCD patients?

Research has shown that exposure therapy, especially when combined with response prevention, is a proven treatment for obsessive-compulsive disorder (OCD). Studies have found it effective and generally safe in both hospital and outpatient settings. For example, one study found that this method helped patients manage their OCD symptoms well.

While exposure therapy is considered safe, some people might feel uncomfortable during sessions. This discomfort arises because the therapy involves facing things that trigger OCD symptoms. However, these feelings are usually temporary and are part of the process to help reduce anxiety over time.

Overall, exposure therapy is well-tolerated, and no significant evidence of long-term negative effects exists. For those considering joining a trial, it is reassuring to know that this treatment has a strong safety record.12345

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores a personalized approach to exposure therapy for OCD. Unlike standard treatments like cognitive-behavioral therapy with exposure and response prevention (ERP), this method involves developing exposure plans collaboratively with participants, tailoring the treatment to their specific needs. Additionally, the use of a wristwatch that gathers psychophysiological data is a novel feature, potentially offering real-time insights into patients' responses and allowing for more precise adjustments. This trial aims to refine exposure therapy practices, potentially enhancing its effectiveness and accessibility for individuals struggling with OCD.

What is the effectiveness track record for exposure therapy in treating OCD?

Research shows that exposure therapy, which participants in this trial will receive, effectively treats obsessive-compulsive disorder (OCD). Studies have found it greatly reduces OCD symptoms. One study found that symptoms improved significantly when exposure therapy was combined with medication, demonstrating a powerful combined approach. Another study found that exposure therapy alone had a moderate effect on reducing OCD symptoms. Overall, exposure therapy is a proven method, but there is still room for improvement for those who don't fully recover.12367

Who Is on the Research Team?

JM

Jennie M Kuckertz, PhD

Principal Investigator

Mclean Hospital

Are You a Good Fit for This Trial?

This trial is for adults aged 18-65 with Obsessive Compulsive Disorder (OCD) who are seeking exposure therapy at McLean Hospital OCD Institute or San Diego State University. Participants must be able to complete study measures and treatment procedures in English.

Inclusion Criteria

You are currently receiving treatment at the McLean Hospital OCD Institute or San Diego State University.
I have been diagnosed with OCD.
You can understand and follow the study instructions in English.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants complete exposure therapy for up to 12 weeks, with each session approximately 50 minutes long. Exposure plans are developed collaboratively and refined iteratively.

12 weeks
Weekly sessions

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Exposure Therapy
Trial Overview The study aims to identify key mechanisms that make exposure therapy effective for treating OCD by analyzing self-reported data, observer-rated behavior, and physiological responses like heart rate during therapy sessions.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Exposure therapyExperimental Treatment1 Intervention

Exposure Therapy is already approved in United States for the following indications:

🇺🇸
Approved in United States as Prolonged Exposure Therapy for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Mclean Hospital

Lead Sponsor

Trials
221
Recruited
22,500+

Published Research Related to This Trial

In a study involving 42 OCD patients, Concentrated Exposure Treatment (cET) led to a significant reduction in OCD symptoms, with 74% of participants achieving remission immediately after treatment and 60% maintaining recovery at a 6-month follow-up.
The treatment was well-received, showing high patient satisfaction, and the effectiveness of cET was successfully replicated with a new group of therapists, indicating its potential for broader use in treating OCD.
Concentrated ERP Delivered in a Group Setting: A Replication Study.Havnen, A., Hansen, B., Öst, LG., et al.[2022]
Exposure therapy with response prevention is considered the most effective treatment for obsessive-compulsive disorder (OCD), highlighting its importance in managing this condition.
This therapy has been successfully applied to both outpatient and inpatient settings, demonstrating its versatility and effectiveness across different patient populations.
[Obsessive-compulsive disorders--inpatient behavior therapy].Winkelmann, G., Hohagen, F.[2006]
A study involving 160 active-duty military personnel with PTSD found that 60-minute prolonged exposure (PE) therapy sessions are just as effective as the standard 90-minute sessions, making treatment more accessible in settings that typically use shorter appointment times.
Both the Clinician Administered PTSD Scale (CAPS-5) and the PTSD Checklist (PCL-5) showed that the efficacy of 60-minute sessions was noninferior to 90-minute sessions, suggesting that shorter sessions can be effectively implemented without compromising treatment outcomes.
The efficacy of 90-min versus 60-min sessions of prolonged exposure for PTSD: A randomized controlled trial in active-duty military personnel.Foa, EB., Bredemeier, K., Acierno, R., et al.[2022]

Citations

Exposure and response prevention for obsessive-compulsive ...Despite the success of ERP in treating OCD, there is room for improvement. As noted above, many people drop out of treatment prematurely and a substantial ...
Preliminary evidence for the effectiveness of concurrent ...These preliminary findings suggest that a concurrent approach to treating co-occurring OCD and PTSD is effective even with dynamic comorbidity.
Exposure Therapy in Mixed Reality for Obsessive ...This evidence-based therapeutic approach has exhibited high effectiveness (Hedges g = 0.74) in reducing symptom severity and improving overall ...
The effectiveness of exposure and response prevention ...Patients with OCD have significant improvement in symptoms of obsessive-compulsive disorder and depression when ERP is combined with medication, ...
The effect of exposure and response prevention therapy on ...The results showed that ERP had a definite effect on OCD (g = 0.37), and its effect was significant when the control condition was placebo (g = 0.97) or drug (g ...
Patient adherence and treatment outcome with exposure ...These data provide an efficient method for differentiating between those patients who will and will not achieve wellness after EX/RP augmentation of SRIs.
effects of habituation and expectancy violation on short-term ...This study aimed to identify mechanisms of exposure with response prevention (ERP) that predict short-term outcomes in CBT for obsessive ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security